Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2008, Article ID 874075, 14 pages
http://dx.doi.org/10.1155/2008/874075
Research Article

Immunohistochemical Estimates of Angiogenesis, Proliferative Activity, p53 Expression, and Multiple Drug Resistance Have No Prognostic Impact in Osteosarcoma: A Comparative Clinicopathological Investigation

1University Institute of Pathology, Aarhus University Hospital, Aarhus Sygehus, THG, 8000 Aarhus, Denmark
2Department of Oncology, Aarhus University Hospital, Aarhus Sygehus, NBG, 8000 Aarhus, Denmark
3Department of Biostatistics, University of Aarhus, 8000 Aarhus, Denmark
4Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus Sygehus, NBG, 8000 Aarhus, Denmark

Received 24 April 2008; Accepted 17 November 2008

Academic Editor: Kees Verhoef

Copyright © 2008 Flemming Brandt Sorensen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. M. Bentzen, H. S. Poulsen, S. Kaae et al., “Prognostic factors in osteosarcomas. A regression analysis,” Cancer, vol. 62, no. 1, pp. 194–202, 1988. View at Publisher · View at Google Scholar
  2. W. F. Taylor, J. C. Ivins, K. K. Unni, J. W. Beabout, H. J. Golenzer, and L. E. Black, “Prognostic variables in osteosarcoma: a multi-institutional study,” Journal of the National Cancer Institute, vol. 81, no. 1, pp. 21–30, 1989. View at Publisher · View at Google Scholar
  3. D. B. Glasser, J. M. Lane, A. G. Huvos, R. C. Marcove, and G. Rosen, “Survival, prognosis, and therapeutic response in osteogenic sarcoma. The memorial hospital experience,” Cancer, vol. 69, no. 3, pp. 698–708, 1992. View at Publisher · View at Google Scholar
  4. P. Bieling, N. Rehan, P. Winkler et al., “Tumor size and prognosis in aggressively treated osteosarcoma,” Journal of Clinical Oncology, vol. 14, no. 3, pp. 848–858, 1996. View at Google Scholar
  5. S. Ferrari, F. Bertoni, M. Mercuri et al., “Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute,” Annals of Oncology, vol. 12, no. 8, pp. 1145–1150, 2001. View at Publisher · View at Google Scholar
  6. A. M. Davis, R. S. Bell, and P. J. Goodwin, “Prognostic factors in osteosarcoma: a critical review,” Journal of Clinical Oncology, vol. 12, no. 2, pp. 423–431, 1994. View at Google Scholar
  7. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar
  8. M. Salzer-Kunstschik, G. Brand, and G. Delling, “Bestimmung des morphologischen regressionsgrades nach chemotherapie bei malignen knochentumoren,” Pathologe, vol. 4, no. 3, pp. 135–141, 1983. View at Google Scholar
  9. P. Picci, G. Bacci, M. Campanacci et al., “Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor,” Cancer, vol. 56, no. 7, pp. 1515–1521, 1985. View at Publisher · View at Google Scholar
  10. R. Jong, A. M. Davis, M. G. Mendes, J. S. Wunder, R. S. Bell, and R. Kandel, “Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases,” Sarcoma, vol. 4, no. 1-2, pp. 47–55, 2000. View at Publisher · View at Google Scholar
  11. N. Gokgoz, J. S. Wunder, S. Mousses, S. Eskandarian, R. S. Bell, and I. L. Andrulis, “Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma,” Cancer, vol. 92, no. 8, pp. 2181–2189, 2001. View at Publisher · View at Google Scholar
  12. N. Baldini, K. Scotlandi, G. Barbanti-Bròdano et al., “Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome,” The New England Journal of Medicine, vol. 333, no. 21, pp. 1380–1385, 1995. View at Publisher · View at Google Scholar
  13. I. J. Lewis, M. A. Nooij, J. Whelan et al., “Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup,” Journal of the National Cancer Institute, vol. 99, no. 2, pp. 112–128, 2007. View at Publisher · View at Google Scholar
  14. E. Mantadakis, G. Kim, J. Reisch et al., “Lack of prognostic significance of intratumoral angiogenesis in nonmetastatic osteosarcoma,” Journal of Pediatric Hematology Oncology, vol. 23, no. 5, pp. 286–289, 2001. View at Publisher · View at Google Scholar
  15. D. Wang, L. Chen, and F. Gao, “Correlation of tumor microvesseldensity with prognosis in osteogenic sarcoma,” Zhonghua Bing Li Xue Za Zhi, vol. 26, no. 5, pp. 266–269, 1997 (Chinese). View at Google Scholar
  16. D. Mikulic, I. Ilic, M. Cepulic et al., “Tumor angiogenesis and outcome in osteosarcoma,” Pediatric Hematology and Oncology, vol. 21, no. 7, pp. 611–619, 2004. View at Publisher · View at Google Scholar
  17. M. Kreuter, R. Bieker, S. S. Bielaek et al., “Prognostic relevance of increased angiogenesis in osteosarcoma,” Clinical Cancer Research, vol. 10, no. 24, pp. 8531–8537, 2004. View at Publisher · View at Google Scholar
  18. E. T. Ek, J. Ojaimi, Y. Kitagawa, and P. F. Choong, “Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?” Oncology Reports, vol. 16, no. 1, pp. 17–23, 2006. View at Google Scholar
  19. J. H. Edmonson, H. J. Long, R. L. Richardson, E. T. Creagan, and S. J. Green, “Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas,” Cancer Chemotherapy and Pharmacology, vol. 15, no. 2, pp. 181–182, 1985. View at Publisher · View at Google Scholar
  20. W. T. Beck, T. M. Grogan, C. L. Willman et al., “Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations,” Cancer Research, vol. 56, no. 13, pp. 3010–3020, 1996. View at Google Scholar
  21. H. J. G. Gundersen, “Notes on the estimation of the numerical density of arbitrary profiles: the edge effect,” Journal of Microscopy, vol. 111, pp. 219–233, 1977. View at Google Scholar
  22. H. W. Chalkley, “Method for the quantitative morphologic analysis of tissues,” Journal of the National Cancer Institute, vol. 4, pp. 47–53, 1943. View at Google Scholar
  23. P. B. Vermeulen, G. Gasparini, S. B. Fox, and C. Colpaert, “Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours,” European Journal of Cancer, vol. 38, no. 12, pp. 1564–1579, 2002. View at Publisher · View at Google Scholar
  24. E. Vollmer, A. Roessner, J. Gerdes et al., “Improved grading of bone tumors with the monoclonal antibody Ki-67,” Journal of Cancer Research and Clinical Oncology, vol. 112, no. 3, pp. 281–282, 1986. View at Publisher · View at Google Scholar
  25. E. Vollmer, A. Roessner, P. Wuisman, A. Härle, and E. Grundmann, “The proliferation behavior of bone tumors investigated with the monoclonal antibody Ki-67,” Current Topics in Pathology, vol. 80, pp. 91–114, 1989. View at Google Scholar
  26. H.-R. Park and Y.-K. Park, “Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone,” Journal of Korean Medical Science, vol. 10, no. 5, pp. 360–367, 1995. View at Google Scholar
  27. M. Pösl, M. Amling, M. Werner et al., “Osteosarkom—apoptose und proliferation untersuchung zur bcl-2-expression,” Der Pathologe, vol. 15, no. 6, pp. 337–344, 1994. View at Publisher · View at Google Scholar
  28. I. Stenzel, M. Pösl, H. Ritzel, M. Hentz, M. Werner, and G. Delling, “Zellproliferation bei knochentumoren immunhistologische untersuchung zur Ki-67-proteinexpression,” Der Pathologe, vol. 17, no. 1, pp. 56–62, 1996. View at Publisher · View at Google Scholar
  29. M. G. C. T. van Oijen, R. H. Medema, P. J. Slootweg, and G. Rijksen, “Positivity of the proliferation marker Ki-67 in noncycling cells,” American Journal of Clinical Pathology, vol. 110, no. 1, pp. 24–31, 1998. View at Google Scholar
  30. K. Okada, J. Nishida, T. Morita, H. Kakizaki, A. Ishikawa, and T. Hotta, “Low-grade intraosseous osteosarcoma in northern Japan: advantage of AgNOR and MIB-1 staining in differential diagnosis,” Human Pathology, vol. 31, no. 6, pp. 633–639, 2000. View at Publisher · View at Google Scholar
  31. Y. Oda, T. Naka, M. Takeshita, Y. Iwamoto, and M. Tsuneyoshi, “Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study,” Human Pathology, vol. 31, no. 6, pp. 709–716, 2000. View at Publisher · View at Google Scholar
  32. K. Scotlandi, M. Serra, M. C. Manara et al., “Clinical relevance of Ki-67 expression in bone tumors,” Cancer, vol. 75, no. 3, pp. 806–814, 1995. View at Publisher · View at Google Scholar
  33. N.A. Hernández-Rodríguez, E. Correa, R. Sotelo et al., “Ki-67: a proliferative marker that may predict pulmonary metastases and mortality of primary osteosarcoma,” Cancer Detection and Prevention, vol. 25, no. 2, pp. 210–215, 2001. View at Google Scholar
  34. M. L. Jensen, B. Schumacher, O. M. Jensen, O. S. Nielsen, and J. Keller, “Extraskeletal osteosarcomas: a clinicopathologic study of 25 cases,” American Journal of Surgical Pathology, vol. 22, no. 5, pp. 588–594, 1998. View at Publisher · View at Google Scholar
  35. D. G. Stefanou, A. V. Nonni, N. J. Agnantis, S. E. Athanassiadou, E. Briassoulis, and N. Pavlidis, “p53/MDM-2 immunohistochemical expression correlated with proliferative activity in different subtypes of human sarcomas: a ten-year follow-up study,” Anticancer Research, vol. 18, no. 6B, pp. 4673–4681, 1998. View at Google Scholar
  36. B. Wadayama, J. Toguchida, T. Yamaguchi, M. S. Sasaki, Y. Kotoura, and T. Yamamuro, “p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas,” British Journal of Cancer, vol. 68, no. 6, pp. 1134–1139, 1993. View at Google Scholar
  37. Y. Oda, B. Wehrmann, K. Radig et al., “Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression,” General & Diagnostic Pathology, vol. 141, no. 2, pp. 97–103, 1995. View at Google Scholar
  38. F. Lonardo, T. Ueda, A. G. Huvos, J. Healey, and M. Ladanyi, “p53 and MDM2 alterations in osteosarcomas. Correlation with clinicopathologic features and proliferative rate,” Cancer, vol. 79, no. 8, pp. 1541–1547, 1997. View at Publisher · View at Google Scholar
  39. Y. Ueda, B. Dockhorn-Dwornizak, S. Blasius et al., “Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone,” Journal of Cancer Research and Clinical Oncology, vol. 119, no. 3, pp. 172–178, 1993. View at Publisher · View at Google Scholar
  40. R. Gorlick, A. G. Huvos, G. Heller et al., “Expression of HER2/erbB-2 correlates with survival in osteosarcoma,” Journal of Clinical Oncology, vol. 17, no. 9, pp. 2781–2788, 1999. View at Google Scholar
  41. T. Naka, T. Fukuda, N. Shinohara, Y. Iwamoto, Y. Sugioka, and M. Tsuneyoshi, “Osteosarcoma versus malignant fibrous histiocytoma of bone in patients older than 40 years. A clinicopathologic and immunohistochemical analysis with special reference to malignant fibrous histiocytoma-like osteosarcoma,” Cancer, vol. 76, no. 6, pp. 972–984, 1995. View at Publisher · View at Google Scholar
  42. P. A. Hall and D. P. Lane, “p53 In tumour pathology: can we trust immunohistochemistry? - revisited!,” The Journal of Pathology, vol. 172, no. 1, pp. 1–4, 1994. View at Publisher · View at Google Scholar
  43. A. Goto, H. Kanda, Y. Ishikawa et al., “Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas,” Japanese Journal of Cancer Research, vol. 89, no. 5, pp. 539–547, 1998. View at Google Scholar
  44. J. Toguchida, T. Yamaguchi, B. Ritchie et al., “Mutation spectrum of the p53 gene in bone and soft tissue sarcomas,” Cancer Research, vol. 52, no. 22, pp. 6194–6199, 1992. View at Google Scholar
  45. K. Radig, R. Schneider-Stock, C. Haeckel, W. Neumann, and A. Roessner, “p53 gene mutations in osteosarcomas of low-grade malignancy,” Human Pathology, vol. 29, no. 11, pp. 1310–1316, 1998. View at Publisher · View at Google Scholar
  46. C. R. Walkley, R. Qudsi, V. G. Sankaran et al., “Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease,” Genes & Development, vol. 22, no. 12, pp. 1662–1676, 2008. View at Publisher · View at Google Scholar
  47. C. W. Miller, A. Aslo, A. Won, M. Tan, B. Lampkin, and H. P. Koeffler, “Alterations of the p53, Rb and MDM2 genes in osteosarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 9, pp. 559–565, 1996. View at Publisher · View at Google Scholar
  48. M.-K. A. Kaseta, L. Khaldi, I. P. Gomatos et al., “Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma,” Journal of Surgical Oncology, vol. 97, no. 3, pp. 259–266, 2008. View at Publisher · View at Google Scholar
  49. Y. B. Park, H. S. Kim, J. H. Oh, and S. H. Lee, “The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma,” International Orthopaedics, vol. 24, no. 6, pp. 307–310, 2001. View at Publisher · View at Google Scholar
  50. H. S. L. Chan, T. M. Grogan, G. Haddad, G. DeBoer, and V. Ling, “P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy,” Journal of the National Cancer Institute, vol. 89, no. 22, pp. 1706–1715, 1997. View at Publisher · View at Google Scholar
  51. K. Radig, C. Hackel, J. Herting et al., “Expression of P-glycoprotein in high grade osteosarcomas with special emphasis on chondroblastic subtype,” General & Diagnostic Pathology, vol. 142, no. 3-4, pp. 139–145, 1997. View at Google Scholar
  52. M. Pösl, M. Amling, K. Grahl et al., “P-glycoprotein expression in high grade central osteosarcoma and normal bone cells. An Immunohistochemical study,” General & Diagnostic Pathology, vol. 142, no. 5-6, pp. 317–325, 1997. View at Google Scholar
  53. M. Serra, K. Scotlandi, M. C. Manara et al., “Analysis of P-glycoprotein expression in osteosarcoma,” European Journal of Cancer, vol. 31, no. 12, pp. 1998–2002, 1995. View at Publisher · View at Google Scholar
  54. S. Ferrari, F. Bertoni, L. Zanella et al., “Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma,” Cancer, vol. 100, no. 9, pp. 1936–1942, 2004. View at Publisher · View at Google Scholar
  55. S. Kakar, M. Mihalov, N. A. Chachlani, L. Ghosh, and H. Johnstone, “Correlation of c-fos, p53, and PCNA expression with treatment outcome in osteosarcoma,” Journal of Surgical Oncology, vol. 73, no. 2, pp. 125–126, 2000. View at Publisher · View at Google Scholar
  56. E. E. Pakos and J. P. A. Ioannidis, “The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis,” Cancer, vol. 98, no. 3, pp. 581–589, 2003. View at Publisher · View at Google Scholar
  57. K. Scotlandi, M. Serra, G. Nicoletti et al., “Multidrug resistance and malignancy in human osteosarcoma,” Cancer Research, vol. 56, no. 10, pp. 2434–2439, 1996. View at Google Scholar
  58. R. A. Trammell, C. B. Johnson, J. R. Barker, R. S. Bell, and D. G. Allan, “Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model,” Journal of Orthopaedic Research, vol. 18, no. 3, pp. 449–455, 2000. View at Publisher · View at Google Scholar
  59. F. J. Hornicek, M. C. Gebhardt, M. W. Wolfe et al., “P-glycoprotein levels predict poor outcome in patients with osteosarcoma,” Clinical Orthopaedics & Related Research, no. 373, pp. 11–17, 2000. View at Publisher · View at Google Scholar
  60. N. Baldini, K. Scotlandi, M. Serra et al., “P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy,” Journal of Orthopaedic Research, vol. 17, no. 5, pp. 629–632, 1999. View at Publisher · View at Google Scholar
  61. S. D. Shnyder, A. J. Hayes, J. Pringle, and C. W. Archer, “P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma,” British Journal of Cancer, vol. 78, no. 6, pp. 757–759, 1998. View at Google Scholar
  62. R. A. Kandel, S. Campbell, S. E. Noble-Topham, R. Bell, and I. L. Andrulis, “Correlation of P-glycoprotein detection by immunohistochemistry with mdr-l mRNA levels in osteosarcomas. Pilot study,” Diagnostic Molecular Pathology, vol. 4, no. 1, pp. 59–65, 1995. View at Publisher · View at Google Scholar
  63. J. S. Wunder, S. B. Bull, V. Aneliunas et al., “MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study,” Journal of Clinical Oncology, vol. 18, no. 14, pp. 2685–2694, 2000. View at Google Scholar
  64. M. Kaya, T. Wada, T. Akatsuka et al., “Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis,” Clinical Cancer Research, vol. 6, no. 2, pp. 572–577, 2000. View at Google Scholar
  65. A. Handa, T. Tokunaga, T. Tsuchida et al., “Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma,” International Journal of Oncology, vol. 17, no. 2, pp. 291–295, 2000. View at Google Scholar
  66. B. L. Coomber, J. Denton, A. Sylvestre, and S. Kruth, “Blood vessel density in canine osteosarcoma,” Canadian Journal of Veterinary Research, vol. 62, no. 3, pp. 199–204, 1998. View at Google Scholar
  67. S. Mori, T. Ueda, S. Kuratsu, N. Hosono, K. Izawa, and A. Uchida, “Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma,” International Journal of Cancer, vol. 61, no. 1, pp. 148–152, 1995. View at Publisher · View at Google Scholar
  68. T. Morishita, Y. Mii, Y. Miyauchi et al., “Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats,” Japanese Journal of Clinical Oncology, vol. 25, no. 2, pp. 25–31, 1995. View at Google Scholar
  69. D. Harms, “New entities, concepts, and questions in childhood tumor pathology,” General & Diagnostic Pathology, vol. 141, no. 1, pp. 1–14, 1995. View at Google Scholar
  70. M. O'Sullivan, V. Budhraja, Y. Sadovsky, and J. D. Pfeifer, “Tumor heterogeneity affects the precision of microarray analysis,” Diagnostic Molecular Pathology, vol. 14, no. 2, pp. 65–71, 2005. View at Publisher · View at Google Scholar
  71. P. D. Lee, S. E. Noble-Topham, R. S. Bell, and I. L. Andrulis, “Quantitative analysis of multidrug resistance gene expression in human osteosarcomas,” British Journal of Cancer, vol. 74, no. 7, pp. 1046–1050, 1996. View at Google Scholar